The Hellenic Association of Pharmaceutical Companies (SFEE) hosted its annual New Year’s reception last week, at which its president, Olympios Papadimitriou, outlined some of the progress made in the past year.
Mr Papadimitriou on the achievements of 2019: “Firstly, the legislative framework for medicinal pricing and chargeback was clearly defined, and the chargeback was completed after a significant delay. A special budget line item to offset investments made by pharmaceutical companies, either in research and development or in production, against clawbacks allocated to them was announced by the Prime Minister himself.
“This acknowledges the aspect of our sector’s contribution to growth while offering a workaround for the reduction of clawbacks. The VAT rate on medicines was aligned at 6%, effectively removing a pointless burden from the pharmaceutical expenditure, which is close to 30 million euros [$33 million].
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze